Sleep disorders in autoimmune encephalitis.
Journal
The Lancet. Neurology
ISSN: 1474-4465
Titre abrégé: Lancet Neurol
Pays: England
ID NLM: 101139309
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
08
07
2020
revised:
21
08
2020
accepted:
25
08
2020
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
15
12
2020
Statut:
ppublish
Résumé
Sleep disorders in people with autoimmune encephalitis have received little attention, probably overshadowed by the presence of other neurological and psychiatric symptoms in this group of conditions. However, sleep disorders are frequent, often severe, and usually persist beyond the acute disease stage, interfering with patients' recovery and quality of life. Because autoimmune encephalitis can affect any brain network involved in sleep initiation and regulation, all types of sleep disorders can occur, with varying distinct associations, frequency, and intensity. Anti-IgLON5 and anti-NMDA receptor encephalitis exemplify two diseases in which sleep disorders are prominent. In anti-IgLON5 disease, sleep disorders were the core symptoms that led to the description of this disease, whereas in anti-NMDA receptor encephalitis, sleep disorders vary according to the disease stage along with other neuropsychiatric symptoms. Comprehensive, systematic, multicentre studies are needed to characterise sleep disorders and their mechanisms in autoimmune encephalitis.
Identifiants
pubmed: 33212053
pii: S1474-4422(20)30341-0
doi: 10.1016/S1474-4422(20)30341-0
pii:
doi:
Substances chimiques
Cell Adhesion Molecules, Neuronal
0
IgLON5 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1010-1022Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.